Autoimmune polyendocrine syndrome cost-effectiveness of therapy: Difference between revisions
Irfan Dotani (talk | contribs) No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Autoimmune polyendocrine syndrome}} | {{Autoimmune polyendocrine syndrome}} | ||
{{ | {{CMG}}; {{AE}} | ||
==Overview== | ==Overview== | ||
==Cost- | |||
==Cost-effectiveness of Therapy== | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
{{ | |||
{{ |
Revision as of 19:50, 14 August 2017
Autoimmune polyendocrine syndrome Microchapters |
Differentiating Autoimmune polyendocrine syndrome from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Autoimmune polyendocrine syndrome cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Autoimmune polyendocrine syndrome cost-effectiveness of therapy |
FDA on Autoimmune polyendocrine syndrome cost-effectiveness of therapy |
CDC on Autoimmune polyendocrine syndrome cost-effectiveness of therapy |
Autoimmune polyendocrine syndrome cost-effectiveness of therapy in the news |
Blogs on Autoimmune polyendocrine syndrome cost-effectiveness of therapy |
Directions to Hospitals Treating Autoimmune polyendocrine syndrome |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: